ArticleBMC public health2026
Antidepressant discontinuation in France from an intersectional perspective: a discrete-time survival analysis within the MAIHDA framework.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAntidepressant (AD) discontinuation before remission is common in depression care, despite guidelines recommending continuation for six months after remission to prevent relapse. Evidence suggests that socially disadvantaged groups are more likely to discontinue treatment despite higher depression severity, which may contribute to widening inequalities in mental health care. Most studies focus on single social characteristics rather than considering complex intersecting social identities. This study examines AD discontinuation over the first year of treatment across intersectional social strata.
methodsWe analysed data from AD users in the French CONSTANCES cohort (N = 44,268; 64% women) linked to the national drug reimbursement register (2007–2021). We assessed AD discontinuation using discrete time survival analysis within a Multilevel Analysis of Individual Heterogeneity and Discriminatory Accuracy (MAIHDA) framework across 36 intersectional social strata based on unique combinations of gender, education, generation, and migration background.
resultsSocial inequities in AD discontinuation between intersectional strata slightly increased over time. Men or women intersecting lower education, younger generations, and migrant backgrounds had a 44% predicted probability of remaining on treatment at month 1 and 12% at month 11. Men or women with higher education, non-migrant status, and belonging to Generation X or the Boomers, had a 66% predicted probability of remaining on treatment at month 1 and 28% at month 11, indicating longer treatment durations.
conclusionsWhile AD discontinuation may sometimes reflect remission, it is also shaped by intersectional social contexts. Our findings show that AD discontinuation is socially patterned, and this could inform comprehensive policies and programs aimed at supporting individuals from social strata that may experience more difficulties in sustaining treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.